CClinicalTrials.gg
CompletedNCT06980233R-AssistUpdated Oct 7, 2026

Reentry Assist (R-Assist)

An interventional study of reentry assistance mobile health app in Substance Use Disorder (SUD), Mental Health Disorder and Criminal Recidivism, sponsored by Meaningful Measurement, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Meaningful Measurement, Inc · Not applicable, Interventional, and Treatment

Updated Oct 7, 2026Now CompletedEnrollment updatedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This project will aim to develop and pilot test, R-Assist, a mobile health application to support individuals with co-occurring substance use and mental health disorders (COD) in their recovery, who have recently released from a participating Massachusetts jail.

Read the detailed description

This Phase I project will develop and test an mHealth app called R-Assist among individuals with COD recently released from a Massachusetts jail. R-Assist will offer four core features, including linkages to community resources via the resource locator, on demand, tailored self-help materials, and self-management/organizational tools. The following two Aims will be tested: Aim 1. R-Assist software and content prototype development. The 4 R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) social determinants of health (SDOH) resource finder; and 4) a dashboard to track R-Assist engagement. Aim 2. A successive cohort study of the R-Assist prototype with participants who have recently left jail (N = 38). This will include three successive field focus group cohorts with 18 participants, followed by a small open pilot with 20 participants. This project's four milestones will be executed in preparation for a larger Phase II trial.

  • Milestone 1 (Months 1-5): R-Assist App Development and Interface Designs

    o No human subjects involvement

  • Milestone 2 (Months 6-7): Initial Evaluation/Refinement of R-Assist

    o To recruit N=18 individuals for this Milestone

  • Milestone 3 (Months 8-10): Open Pilot of R-Assist

    o To recruit recruit N=20 individuals for this Milestone

  • Milestone 4 (Months 11-12): Product Refinement Prior to Phase II and Dissemination o No human subjects involvement
02

Conditions studied

  • Substance Use Disorder (SUD)
  • Mental Health Disorder
  • Criminal Recidivism

Keywords

  • substance use disorder
  • mental health
  • criminal-legal involvement
03

In context

Substance-Related Disorders

2,124 studies on the registry are indexed under Substance-Related Disorders; 393 are open to participants now.

This study's enrollment of 44 is below the median of 108 across 1,727 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

This is the only study on the registry with Meaningful Measurement, Inc as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Have been released from the participating jail within the past 150 days
  • Own a smartphone (Android or iOS; 90% met this criterion in our prior studies)
  • Have COD: any substance use disorder (we will allow poly-substance use disorders) and a co-occurring mental health disorder (depression, anxiety, trauma related disorders, bipolar, and/or schizophrenia)
  • Consent to R-Assist app use observation and e-tracking
  • Consent to audio recording during interviews and focus groups.

Exclusion criteria

Exclusion Criteria:

  • Acutely suicidal, homicidal, or psychotic
  • Unable to provide informed consent
  • Individuals released with monitoring devices or individuals involved in drug treatment courts
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    R-Assist

    Participants who have recently released from jail will engage with the R-assist app for up to 1.5 months

    Behavioral: reentry assistance mobile health app

Interventions

  • Behavioralreentry assistance mobile health app

    R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session MISSION-CJ self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) SDOH resource finder; and 4) a dashboard to track R-Assist engagement.

06

What researchers measure

Primary outcomes

  1. App usage

    Total time engaged in app will be tracked daily during open pilot period. Additionally, engagement and time with each feature will be tracked

    Time frame: From enrollment for 1.5 months during the open pilot

  2. System Usability Scale (SUS)

    Overall score will be computed, indicating overall usability Score ranges from 0-100 (0-64=not acceptable, 65-84=acceptable, and 85, 100=excellent.

    Time frame: From enrollment for 1.5 months during the open pilot

  3. Mobile Application Rating Scale (MARS)

    Overall score will be computed, indicating overall acceptability, as well as score for each of the four dimensions. The rating scale assesses app quality on four dimensions (1. Engagement, 2. Functionality, 3. Aesthetics, and 4. Information). All items are rated on 5-point scale from "1=inadequate" to "5=excellent"

    Time frame: From enrollment for 1.5 months during the open pilot

  4. Composite International Diagnostic Instrument for DSM-IV: Social determinants of health (SDOH) linkages

    SDOH needs (e.g., housing instability, food insecurity, NA/AA/ other recovery linkages) will be assessed and the App will track all referrals and SDOH linkages made. Percent of linkages made to needed SDOH services will be examined.

    Time frame: From enrollment for 1.5 months during the open pilot

  5. Composite International Diagnostic Instrument for DSM-IV: Substance Use Disorder

    Substance use disorder symptoms will be tracked daily during the open pilot period.

    Time frame: From enrollment for 1.5 months during the open pilot

  6. Composite International Diagnostic Instrument for DSM-IV: Mental Health

    Mental health symptoms will be tracked daily during the open pilot period.

    Time frame: From enrollment for 1.5 months during the open pilot

07

Study locations

1 site
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01605, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Enrollment
38 (estimated)→44 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    Enrollment 38 (estimated)→44 (actual)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06980233
Lead sponsor
Meaningful Measurement, Inc
Collaborators
National Institute on Drug Abuse (NIDA), University of Massachusetts, Worcester
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Jun 1, 2025
Primary completion
Mar 31, 2026
Completion
Apr 30, 2026
Last update
Oct 7, 2026

Study contacts

David Smelson, PsyD
principal investigator · University of Massachusetts, Worcester
Donna Surges Tatum, PhD
principal investigator · Meaningful Measurement, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion